Related Experiment Video

Updated: May 31, 2026

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

Exploring anti-TGF-β therapies in cancer and fibrosis

Lukas J A C Hawinkels1, Peter Ten Dijke

  • 1Department of Molecular Cell Biology and Centre for Biomedical Genetics, Leiden University Medical Center, Leiden, The Netherlands.

Growth Factors (Chur, Switzerland)
|July 2, 2011
PubMed

Insights

Transforming growth factor-β (TGF-β) therapies target its role in diseases like cancer and fibrosis. This review examines current clinical trials for anti-TGF-β treatments, offering hope for managing these conditions.

Area of Science:

  • Molecular Biology
  • Cell Signaling
  • Immunology

Background:

  • Transforming growth factor-β (TGF-β) is a key cytokine regulating tissue homeostasis.
  • Dysregulated TGF-β signaling is linked to cancer, fibrosis, and systemic sclerosis, often correlating with disease severity.
  • TGF-β promotes tumor invasion, metastasis, fibroblast activation, immune suppression, and extracellular matrix deposition.

Purpose of the Study:

  • To review the current status of anti-TGF-β therapies in clinical trials.
  • To provide an overview of therapeutic strategies targeting TGF-β signaling pathways.
  • To highlight the potential of TGF-β inhibition in treating various pathological conditions.

Main Methods:

  • Review of existing literature on TGF-β signaling and therapeutic interventions.
  • Analysis of clinical trial data for anti-TGF-β agents.
  • Summary of different therapeutic approaches including small molecule inhibitors, neutralizing antibodies, antisense oligonucleotides, and soluble receptors.

Main Results:

  • Multiple therapeutic strategies targeting TGF-β signaling are under investigation in clinical trials.
  • These therapies aim to counteract the detrimental effects of excessive TGF-β in diseases like cancer and fibrosis.
  • The development of these agents reflects the significant role of TGF-β in various pathological processes.

Conclusions:

  • Anti-TGF-β therapies represent a promising avenue for treating diseases associated with aberrant TGF-β signaling.
  • Clinical trials are evaluating the efficacy and safety of diverse therapeutic modalities.
  • Further research and clinical evaluation are crucial to establish the role of these therapies in patient care.

More Related Videos

Spheroid Assay to Measure TGF-β-induced Invasion09:18

Spheroid Assay to Measure TGF-β-induced Invasion

Published on: November 16, 2011

A Mouse Model to Investigate the Role of Cancer-Associated Fibroblasts in Tumor Growth06:35

A Mouse Model to Investigate the Role of Cancer-Associated Fibroblasts in Tumor Growth

Published on: December 22, 2020

Related Concept Videos

TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Introduction to Fibroblasts01:09

Introduction to Fibroblasts

Rudolph Virchow discovered spindle-shaped cells called fibroblasts in 1858. Inactive fibroblasts, called fibrocytes, become activated by various stimuli, such as growth factors and inflammatory cytokines. Activated fibroblasts play a crucial role in wound healing, inflammation, formation of new blood vessels, and cancer progression. Uncontrolled activation of fibroblasts results in fibrosis, the excess deposition of fibrous tissue, which can lead to scarring and affect normal organs. This...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...